ライフサイエンスコーパス: further investigation

1 Further investigation implicated p53 as a transcription facto

2 Further investigation in the inhibitory versus excitatory neu

3 Further investigation into the basis for ASO-FUS binding illu

4 Further investigation of drugs targeting chromatin regulators

5 Further investigation revealed that increased mitochondrial f

6 Further investigation suggested that CCL5, secreted from HCV-

7 Further investigations are needed to determine possible roles

8 Further investigations revealed that the GAC polyrhamnose bac

9 Although further investigations are required to determine the degree t

10 chemical reaction products is clearly problematic and bears further investigation.

11 that S17 is a leadbrominated chalcone derivate and deserves further investigation for prevention and treatment of gastric

12 ance and the adverse side effect profiles of many TB drugs, further investigation of lansoprazole as a potential antitube

13 The panel also identified key areas for further investigation.

14 e any gene but FOXI2, FANK1 and GLRX3 remain candidates for further investigation.

15 GBM treatment resistance while also providing direction for further investigation.

16 Our findings provide impetus for further investigation of this compound as a novel adjunct the

17 Among all, DDQ was selected for further investigation because of 1) its best docking score an

18 The project produced a large data set for further investigation of coreference and coreference resoluti

19 mphigus pathogenesis, it aims to serve as a solid basis for further investigations for the entire field.

20 Our data represent a comprehensive resource for further investigations on the role of the gut microbiome in p

21 However, further investigations on molecular events and pathways respo

22 Our results justify further investigation of AT with kinase inhibitors.

23 BV is tolerable and has activity in SR-aGVHD and merits further investigation.

24 ditional benefit for esophageal cancer patients, and merits further investigation.

25 on clinical measures of fibrosis risk stratification merits further investigation.

26 es such as behavioral deficits is a possibility that merits further investigation.

27 These data suggest that DNA vaccination merits further investigation as a potential means to reduce ZIKV per

28 nics and represents a clinically relevant factor that needs further investigation.

29 HGEF1 in asthmatic airway hyper-responsiveness is worthy of further investigation.

30 These results promote further investigation of vmPFC safety signaling in other anxi

31 , hopefully facilitating clinical decision making regarding further investigations and the need for antibiotics.

32 merase inhibitors are attractive possibilities that require further investigation.

33 n treatment for primary prevention in older adults requires further investigation.

34 varian cancer risk is still somewhat uncertain and requires further investigation.

35 ciated with the lack of IL-1R signaling in mice and support further investigation into the role of IL-1 ligands in epider

36 is active in relapsed/refractory PCNSL and PTL and support further investigation of PD-1 blockade in these diseases.

37 e ciproxifan shows only moderate activity at human targets, further investigations in animals are not of primary interest

38 c uveal melanoma is immunotherapy resistant and support the further investigation of immune-based therapies for this canc

39 Undoubtedly, further investigations are required to best inform future gui

40 The findings warrant further investigation and may provide a therapeutic opportuni

41 s, or fibrosis stage, whereas lipid alterations may warrant further investigation.

42 Many of these mutations warrant further investigation as potential cancer drivers.

43 cytotoxicity, growth and cytokine response, thus warranting further investigation into the interfacial effects of small c

44 of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation.

45 , but the overall picture remains inconclusive and warrants further investigation.

46 Cystatin C warrants further investigation as a more meaningful measure of renal f

47 ing on significant haematoma expansion at 24 hours warrants further investigation.

48 g plant stress tolerance mechanisms including NTSR warrants further investigation.

49 r biological relevance, and therefore, the premise warrants further investigation.

50 This warrants further investigation on molecular pathways involved in both